

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Equality and health inequality impact assessment

Oveporexton for treating type 1 narcolepsy [ID6622]

Scoping

1 Have any potential equality issues been identified during the scoping process? If so, what are they?

At consultation, stakeholders raised the following equality issues:

- Usual first-line treatment for narcolepsy, modafinil, can increase the risk of congenital malformations if used during pregnancy, and so should not be used during pregnancy.

2 Have any potential health inequality issues been identified during the scoping process? If so, what are they?

At consultation, stakeholders raised the following health inequality issues:

- people with narcolepsy who have poor disease control may not be able to drive or access geographically remote specialist clinics and there are relatively few specialist sleep clinics in the UK. Ethnic minority groups and people with disabilities are over-represented in this group.
- the sedative effects of sodium oxybate can be dangerous for young people living in shared accommodation or people with caring responsibilities.

3 What is the preliminary view as to what extent the committee needs to address the potential issues set out in questions 1 and 2?

The committee will consider all relevant equality and health inequality issues in its deliberations.

- 4 Has any change to the draft scope been agreed to highlight the potential equality or health inequality issues set out in questions 1 and 2 following the scope consultation?**

No.

- 5 Has the stakeholder list been updated as a result of additional equality or health inequality issues identified during the scoping process?**

No.

Approved by senior responsible officer: Adam Brooke

Date: 22/06/2026